Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

PHASE3RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Familial Partial Lipodystrophy
Interventions
DRUG

Metreleptin

Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

Trial Locations (6)

33434

NOT_YET_RECRUITING

Flourish Research, Boca Raton

35233

NOT_YET_RECRUITING

University of Alabama, Birmingham

48109

RECRUITING

University of Michigan, Ann Arbor

53226

RECRUITING

The Medical College of Wisconsin, Milwaukee

75390

RECRUITING

UT Southwestern Medical Center, Dallas

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amryt Pharma

INDUSTRY